Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma.
Eric S ChristensonSu Jin LimJennifer N DurhamAna M C De Jesus-AcostaKatherine M BeverDaniel A LaheruAmy RyanParul AgarwalRobert B ScharpfDung T LeHao WangPublished in: Cancer research communications (2022)
We report on the association of cfDNA with response durability for patients undergoing treatment with a novel metronomic chemotherapy regimen (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan; GAX-CI) for metastatic PDAC. This investigation offers encouraging evidence that cfDNA may prove to be a valuable diagnostic tool to guide clinical management.